Mark Iwicki is Chief Executive Officer and Director of Inhibikase Therapeutics, Inc. (IKT). The company reported total compensation of $30,586,007 for fiscal year 2025.
| Salary | $624,208 |
|---|---|
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $29,429,299 |
| Non-equity incentive plan | $532,500 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $0 |
| Total | $30,586,007 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Inhibikase Therapeutics, Inc. filed April 30, 2026, accession 0001193125-26-197177.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Mark Iwicki this page | Chief Executive Officer and Director | $30,586,007 |
| Chris Cabell, M.D. | President and Head of Research and Development | $7,475,289 |
| David McIntyre | Chief Financial Officer | $5,519,690 |
| Milton Werner, Ph.D. | Former President and Chief Executive Officer | $803,063 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Inhibikase Therapeutics, Inc. compensation brief.
Mark Iwicki's compensation sits inside Inhibikase Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.